Date Issued: 5/25/2017
Please note that coding for the following medical technology has been updated. To learn more about this update, visit our Medical Technologies Database webpage. Open the document, and scroll (or search) to the view the coding section for this technology. The clinical criteria for this policy hasn’t changed.
- Genetic testing — acute myeloid leukemia (AML) therapeutic management
- CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha [a]), full gene sequence analysis FLT3 gene analysis
